Intranasal corticosteroids:

• are first-choice treatment for patients with allergic rhinitis.
  They are more effective than oral antihistamines in controlling rhinitis symptoms, particularly nasal congestion.
   
• have a good long-term safety profile.
  Nosebleed (usually minor and self-limiting) is the most commonly reported adverse effect. They do not have a clinically significant effect on the hypothalamic–pituitary– adrenal axis or cause mucosal atrophy when used continuously.

PDF Download

Intranasal Corticosteroid Spray Technique

Acknowledgements

This information paper was prepared in consultation with the following health professionals:

Associate Professor Richard Harvey, ear, nose and throat surgeon
Professor Connie Katelaris, allergist and immunologist
Ms Cheryl Tite, pharmacist
Dr Simon Young, general practitioner

Disclaimer

Although all care has been taken, this information paper is a general guide only, which is not intended to be a substitute for assessment of appropriate courses of treatment on a case-by-case basis. The National Asthma Council Australia expressly disclaims all responsibility (including for negligence) for any loss, damage or personal injury resulting from reliance on the information contained herein.

Suggested Citation

National Asthma Council Australia. Intranasal corticosteroid spray technique for people with allergic rhinitis. Melbourne: National Asthma Council Australia, 2010.